Literature DB >> 24990095

Zebrafish as a new model for phenotype-based screening of positive inotropic agents.

Chunlei Tang1, Desheng Xie, Bainian Feng.   

Abstract

The zebrafish-based assay is a widely used animal model system for cardiovascular research. In this study, we investigated the cardiac defects caused by terfenadine and tested the pharmacological response of digoxin to zebrafish with cardiac defects. The study suggested that zebrafish could be a suitable model for phenotype-based screening and evaluation of positive inotropic agents. This phenotype-based heart failure zebrafish model system was then utilized in in-house library screen. Some positive inotropic compound was discovered, which could attenuate the cardiac defects by increasing the flow velocity of caudal artery blood.
© 2014 John Wiley & Sons A/S.

Entities:  

Keywords:  heart failure; phenotype-based; positive inotropic agent; zebrafish

Mesh:

Substances:

Year:  2014        PMID: 24990095     DOI: 10.1111/cbdd.12389

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  3 in total

1.  Zebrafish Larvae Model of Dilated Cardiomyopathy Induced by Terfenadine.

Authors:  Gyojeong Gu; Yirang Na; Hyewon Chung; Seung Hyeok Seok; Hae Young Lee
Journal:  Korean Circ J       Date:  2017-09-20       Impact factor: 3.243

2.  Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway.

Authors:  Nana Ai; Cheong-Meng Chong; Weiting Chen; Zhe Hu; Huanxing Su; Guokai Chen; Queenie Wing Lei Wong; Wei Ge
Journal:  Oncotarget       Date:  2018-01-10

3.  Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure.

Authors:  Hailian Quan; Gyu Chul Oh; Seung Hyeok Seok; Hae-Young Lee
Journal:  Korean J Intern Med       Date:  2020-03-13       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.